Findings

What do systematic reviews say?

311 questions · 323 findings · 30 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 47 · 14.6%GRADE not reported 21 · 6.5%Very low 91 · 28.2%Low 65 · 20.1%Moderate 82 · 25.4%High 17 · 5.3%

Eculizumab vs placebo or alternative treatment

Death · children and adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
100 participants
Very low

Ravulizumab vs placebo or alternative treatment

Remission · adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
56 participants
Very low

Ravulizumab vs placebo or alternative treatment

Change in eGFR · adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
56 participants
Very low

Ravulizumab vs placebo or alternative treatment

Health‐related quality of life · adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
44 participants
Very low

Ravulizumab vs placebo or alternative treatment

Adverse events · adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
58 participants
Very low

Ravulizumab vs placebo or alternative treatment

Meningococcal infection · adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
58 participants
Very low

Eculizumab vs placebo or alternative treatment

Requirement for KRT · children and adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
100 participants
Very low

Eculizumab vs placebo or alternative treatment

Remission · children and adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
100 participants
Very low

Eculizumab vs placebo or alternative treatment

Change in eGFR · children and adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
88 participants
Very low

Eculizumab vs placebo or alternative treatment

Health‐related quality of life · children and adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
100 participants
Very low

Eculizumab vs placebo or alternative treatment

Adverse events · children and adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
100 participants
Very low

Eculizumab vs placebo or alternative treatment

Meningococcal infection · children and adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
100 participants
Very low

Ravulizumab vs placebo or alternative treatment

Death · adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
58 participants
Very low

Ravulizumab vs placebo or alternative treatment

Requirement for KRT · adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
56 participants
Very low

RISPERIDONE vs placebo

Aggression · Disruptive behaviours in children and youths

2 findings from 1 review

Atypical antipsychotics for disruptive behaviour disorders in children and youths 2017 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 238 participants
Low
Atypical antipsychotics for disruptive behaviour disorders in children and youths 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 190 participants
Moderate

RISPERIDONE vs placebo

Conduct · Disruptive behaviours in children and youths

1 finding from 1 review

Atypical antipsychotics for disruptive behaviour disorders in children and youths 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 225 participants
Moderate

RISPERIDONE vs placebo

Weight gain · Disruptive behaviours in children and youths

2 findings from 1 review

Atypical antipsychotics for disruptive behaviour disorders in children and youths 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 138 participants
Moderate
Atypical antipsychotics for disruptive behaviour disorders in children and youths 2017 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 305 participants
Low

CHLORPROMAZINE vs OLANZAPINE

Global state: No clinically significant response (as defined by the original studies) · patients with schizophrenia

CHLORPROMAZINE may leads to higher no significant clinical response: short term (up to 6 months) compared with OLANZAPINE (low certainty).

1 finding from 1 review

Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes only
RR 2.34 [1.37, 3.99]
3 studies · 204 participants
Low

CHLORPROMAZINE vs RISPERIDONE

QoL · patients with schizophrenia

1 finding from 1 review

Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 100 participants
Very low

CHLORPROMAZINE vs RISPERIDONE

Leaving the study early ‐ due to adverse effects (short term) · patients with schizophrenia

It is very uncertain whether CHLORPROMAZINE changes leaving the study early due to adverse effects ‐ short term (up to 6… compared with RISPERIDONE (very low certainty).

1 finding from 1 review

Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes only
RR 0.21 [0.01, 4.11]
1 study · 41 participants
Very low